Newer antipsychotics and upcoming molecules for schizophrenia (Q38094930)

28 August 2017

Newer antipsychotics and upcoming molecules for schizophrenia (English)

1 reference

28 August 2017

1 reference

Melvin George

1

1 reference

28 August 2017

Radhika Amrutheshwar

2

1 reference

28 August 2017

Ravi Philip Rajkumar

3

1 reference

28 August 2017

Shivanand Kattimani

4

1 reference

28 August 2017

Steven Aibor Dkhar

5

1 reference

28 August 2017

2 April 2013

1 reference

European Journal of Clinical Pharmacology

28 August 2017

1 reference

28 August 2017

69

1 reference

28 August 2017

8

1 reference

28 August 2017

1497-1509

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-013-1498-4

28 August 2017

0 references

cites work

Managing suicide risk in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Functional neuroimaging in schizophrenia: diagnosis and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Iloperidone: A new drug for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Iloperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Evaluation of the clinical efficacy of asenapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Role of sublingual asenapine in treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Lurasidone: a new treatment option for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Clinical potential of lurasidone in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Lurasidone: a new drug in development for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Blonanserin: a review of its use in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Effect of dose timing in relation to food intake on systemic exposure to blonanserin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Blonanserin in the treatment of delirium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activiti

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Immediate and sustained improvements in working memory after selective stimulation of α7 nicotinic acetylcholine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Initial phase 2 trial of a nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Exacerbation of recurrent depression as a result of treatment with varenicline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Novartis to shut brain research facility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Glycine transporter-1: a new potential therapeutic target for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-013-1498-4

Exacerbation of schizophrenia by varenicline

21 January 2018

1 reference

12 December 2020

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia

1 reference

12 December 2020

Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration

1 reference

12 December 2020

Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia

1 reference

12 December 2020

A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors

1 reference

12 December 2020

Lurasidone (Latuda) for schizophrenia

1 reference

12 December 2020

The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats

1 reference

12 December 2020

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia

1 reference

12 December 2020

Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy

1 reference

12 December 2020

Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia

1 reference

12 December 2020

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

1 reference

12 December 2020

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

1 reference

12 December 2020

A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia

1 reference

12 December 2020

10.1007/S00228-013-1498-4

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference